---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Humanistic burden and health-related quality of life. Topics: Patient-reported impact on daily life: multinational survey, Real-world deterioration of health-related quality of life and pain, Health state utility values by disease state, Pooled health state utility values by line of therapy: meta-analysis, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Patient-reported impact on daily life: multinational survey

> “A total of 221 patients with mCRPC and 159 caregivers from USA, France, Germany, Canada, Spain, China, and Brazil were surveyed. mCRPC impacts mood, emotional and mental health (50–77%), sleep (48–68%), career goals (48–80%), and social activities (46–65%).”
> “Patients face high treatment and pill burden (7–12 pills/day) and prefer simpler treatment regimens.”
> “For many patients (52% to 73%), ≥9 hours per week were devoted to mCRPC care.”
> “One in three patients experiences fatigue, which is persistent and happens during day-to-day activities (Figure 2(b)).”

Source: [Jain et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218467/)

<a id="topic-2.2.1.8.1-2"></a>

### Real-world deterioration of health-related quality of life and pain

> “In total, 151 included patients answered 873 questionnaires.”
> “At inclusion, generic HRQoL was high with a mean EQ visual analog score of 73.2 out of 100. The lowest scores were reported on role and physical functioning (mean scores of 69 and 76 of 100, respectively), and fatigue, pain, and insomnia were the most impaired domains. These domains deteriorated in > 50% of patients.”
> “mCRPC has a negative impact on HRQoL with deterioration in all domains over time, especially role and physical functioning.”

Source: [Kuppen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31883940/)

<a id="topic-2.2.1.8.1-3"></a>

### Health state utility values by disease state

> “Data were collected from a total sample of 163 men with metastatic CRPC. Utility values elicited by the EQ-5D-5L ranged from 0.830 for the asymptomatic/mildly symptomatic before chemotherapy disease state (95% confidence interval [CI] 0.795-0.865) to 0.625 for the symptomatic before chemotherapy disease state (95% CI 0.577-0.673).”
> “EORTC-8D utilities ranged from 0.856 (95% CI 0.831-0.882) to 0.697 (95% CI 0.664-0.731) for the same disease/treatment states.”

Source: [Lloyd et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26686802/)

<a id="topic-2.2.1.8.1-4"></a>

### Pooled health state utility values by line of therapy: meta-analysis

> “In primary studies, baseline EQ-5D index utility values ranged from 0.7 to 0.9 in 1L and 0.63 to 0.7 in 2L+.”
> “The pooled mean baseline EQ-5D index utility value was estimated as 0.79 (95% CI, 0.70–0.84) and 0.69 (95% CI, 0.67–0.71) for 1L (n = 7 studies) and 2L + (n = 4 studies), respectively.”
> “The pooled mean baseline EQ VAS score was estimated as 74.63 (95% CI, 70.97–78.29) and 65.82 (95% CI, 64.53–67.11) in 1L and 2L+, respectively.”

Source: [Castro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311294/)

<a id="topic-2.2.1.8.1-5"></a>

### Time to worsening after progression on one androgen receptor pathway inhibitor

> “Eligible patients had metastatic castration-resistant prostate cancer, were candidates for ARPI change after one progression on a previous ARPI”
> “In the [177Lu]Lu-PSMA-617 versus ARPI change groups, median time to worsening in FACT-P total score was 7·46 months (95% CI 6·08-8·54) versus 4·27 months (3·45-4·50; hazard ratio [HR] 0·61 [95% CI 0·50-0·75]), in EQ-5D-5L utility score was 6·28 months (4·70-7·89) versus 3·88 months (3·25-4·44; 0·67 [0·54-0·82]), and in BPI-SF pain intensity was 5·03 months (4·40-6·80) versus 3·65 months (3·09-4·37; 0·72 [0·59-0·88]).”
> “median time to first symptomatic skeletal event was not reached (95% CI not estimable [NE]-NE) in the [177Lu]Lu-PSMA-617 group versus 17·97 months (14·26-NE) in the ARPI change group (HR 0·41 [0·26-0·63]).”

Source: [Fizazi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40441170/)

<a id="topic-2.2.1.8.1-6"></a>

### Pain progression with a second androgen receptor pathway inhibitor after docetaxel

> “Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p<0·0001). Median time to pain progression was not estimable (NE; 95% CI NE-NE) with cabazitaxel and 8·5 months (4·9-NE) with abiraterone or enzalutamide (hazard ratio [HR] 0·55, 95% CI 0·32-0·97; log-rank p=0·035).”
> “Median time to FACT-P total score deterioration was 14·8 months (95% CI 6·3-NE) with cabazitaxel and 8·9 months (6·3-NE) with abiraterone or enzalutamide (HR 0·72, 95% CI 0·44-1·20; log-rank p=0·21).”

Source: [Fizazi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32926841/)

<a id="topic-2.2.1.8.1-7"></a>

### Pain, skeletal events, and health-related quality of life after taxane and androgen receptor pathway inhibitor

> “Pain in patients with mCRPC can be attributed largely to bone metastases, lumbosacral invasion, and nerve root compression, and is associated with shortened OS.”
> “Time to worsening was delayed in the 177Lu-PSMA-617 plus SoC group (n = 385) versus SoC alone (n = 196) for FACT-P total score (HR, 0·46; 95% CI: 0·35, 0·61) and subdomains, BPI-SF pain intensity score (HR, 0·45; 95% CI: 0·33, 0·60) and EQ-5D-5L utility score (HR, 0·49; 95% CI: 0·40, 0·62).”
> “SSEs occurred in 60/385 patients (16%) in the 177Lu-PSMA-617 group and 34/196 patients (17%) in the control group (table 2). The predominant types of SSE were radiation to relieve bone pain, followed by spinal cord compression (table 2).”

Source: [Fizazi et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10641914/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
